Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat B-cell Lymphoma and autoimmunity. Its CAR T-cell programs include FT819 to treat systemic lupus erythematosus, and FT825 to treat solid tumors.It has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of solid tumors. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Metric	Value
Current Market Cap	$137.24M
Last Price	$1.27
52-Week High	$1.94
52-Week Low	$0.68

	A	B	C	D
1	Symbol	Price	Change	Volume
2	FATE	$1.27	+8.05%	1.18M
3
4
5

Fate Therapeutics Inc. (FATE) Market Capitalization

Market Cap Data

Get Fate Therapeutics Inc. Data in Excel

More FATE Financial Data